Related references
Note: Only part of the references are listed.Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
Guadalupe Antelo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: 2019 Update on Diagnosis, Risk-stratification, and Management
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial
Yasuyoshi Morita et al.
CANCER SCIENCE (2018)
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
Maura Nicolosi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Chetasi Talati et al.
SEMINARS IN HEMATOLOGY (2017)
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
R. S. Komrokji et al.
ANNALS OF ONCOLOGY (2016)
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing
Mrinal M. Patnaik et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
A. Tefferi et al.
BLOOD CANCER JOURNAL (2016)
Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Joseph A. Clara et al.
CANCER BIOLOGY & MEDICINE (2016)
Treatment of refractory anemia with ring sideroblasts associated with marked thrombocytosis with lenalidomide in a patient testing negative for 5q deletion and JAK2 V617F and MPL W515K/L mutations
Ryan Keen et al.
HEMATOLOGY REPORTS (2016)
Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with jak2 (V617F) mutation
Ilaria Nichele et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Refractory anemia with ring sideroblasts
Luca Malcovati et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis
Julien Broseus et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis
Gerwin Huls et al.
BLOOD (2010)
Azacitidine in lower-risk myelodysplastic syndromes
Valeria Santini
LEUKEMIA RESEARCH (2009)
The Role of JAK2 Mutations in RARS and Other MDS
E. Hellstrom-Lindberg et al.
Hematology-American Society of Hematology Education Program (2008)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza et al.
BLOOD (2008)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
